Trial Profile
Neoadjuvant Letrozole and Lapatinib in Postmenopausal Women With ER and Her2 Positive Breast Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Letrozole (Primary)
- Indications Early breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Acronyms Neo-All-In
- 11 Oct 2016 Results of explorative mutational analysis (n=21) presented at the 41st European Society for Medical Oncology Congress.
- 19 Nov 2013 Planned end date changed from 1 Apr 2013 to 1 Apr 2015 as reported by ClinicalTrials.gov record.
- 21 Jan 2011 New trial record